Biocompatible PLGA-mesoporous silicon microspheres for the controlled release of bmp-2 for bone augmentation

Research output: Contribution to journalArticle

Silvia Minardi, Joseph S. Fernandez-Moure, Dongmei Fan, Matthew B. Murphy, Iman K. Yazdi, Xuewu Liu, Bradley K. Weiner, Ennio Tasciotti

Bone morphogenetic protein-2 (BMP-2) has been demonstrated to be one of the most vital osteogenic factors for bone augmentation. However, its uncontrolled administration has been associated with catastrophic side effects, which compromised its clinical use. To overcome these limitations, we aimed at developing a safer controlled and sustained release of BMP-2, utilizing poly(lactic-co-glycolic acid)-multistage vector composite microspheres (PLGA-MSV). The loading and release of BMP-2 from PLGA-MSV and its osteogenic potential in vitro and in vivo was evaluated. BMP-2 in vitro release kinetics was assessed by ELISA assay. It was found that PLGA-MSV achieved a longer and sustained release of BMP-2. Cell cytotoxicity and differentiation were evaluated in vitro by MTT and alkaline phosphatase (ALP) activity assays, respectively, with rat mesenchymal stem cells. The MTT results confirmed that PLGA-MSVs were not toxic to cells. ALP test demonstrated that the bioactivity of BMP-2 released from the PLGA-MSV was preserved, as it allowed for the osteogenic differentiation of rat mesenchymal stem cells, in vitro. The biocompatible, biodegradable, and osteogenic PLGA-MSVs system could be an ideal candidate for the safe use of BMP-2 in orthopedic tissue engineering applications.

Original languageEnglish (US)
Article number118
JournalPharmaceutics
Volume12
Issue number2
DOIs
StatePublished - Feb 1 2020

Altmetrics

Cite this

Standard

Biocompatible PLGA-mesoporous silicon microspheres for the controlled release of bmp-2 for bone augmentation. / Minardi, Silvia; Fernandez-Moure, Joseph S.; Fan, Dongmei; Murphy, Matthew B.; Yazdi, Iman K.; Liu, Xuewu; Weiner, Bradley K.; Tasciotti, Ennio.

In: Pharmaceutics, Vol. 12, No. 2, 118, 01.02.2020.

Research output: Contribution to journalArticle

Harvard

Minardi, S, Fernandez-Moure, JS, Fan, D, Murphy, MB, Yazdi, IK, Liu, X, Weiner, BK & Tasciotti, E 2020, 'Biocompatible PLGA-mesoporous silicon microspheres for the controlled release of bmp-2 for bone augmentation' Pharmaceutics, vol. 12, no. 2, 118. https://doi.org/10.3390/pharmaceutics12020118

APA

Minardi, S., Fernandez-Moure, J. S., Fan, D., Murphy, M. B., Yazdi, I. K., Liu, X., ... Tasciotti, E. (2020). Biocompatible PLGA-mesoporous silicon microspheres for the controlled release of bmp-2 for bone augmentation. Pharmaceutics, 12(2), [118]. https://doi.org/10.3390/pharmaceutics12020118

Vancouver

Minardi S, Fernandez-Moure JS, Fan D, Murphy MB, Yazdi IK, Liu X et al. Biocompatible PLGA-mesoporous silicon microspheres for the controlled release of bmp-2 for bone augmentation. Pharmaceutics. 2020 Feb 1;12(2). 118. https://doi.org/10.3390/pharmaceutics12020118

Author

Minardi, Silvia ; Fernandez-Moure, Joseph S. ; Fan, Dongmei ; Murphy, Matthew B. ; Yazdi, Iman K. ; Liu, Xuewu ; Weiner, Bradley K. ; Tasciotti, Ennio. / Biocompatible PLGA-mesoporous silicon microspheres for the controlled release of bmp-2 for bone augmentation. In: Pharmaceutics. 2020 ; Vol. 12, No. 2.

BibTeX

@article{b0c3e400611f4fa4a7459a569983c543,
title = "Biocompatible PLGA-mesoporous silicon microspheres for the controlled release of bmp-2 for bone augmentation",
abstract = "Bone morphogenetic protein-2 (BMP-2) has been demonstrated to be one of the most vital osteogenic factors for bone augmentation. However, its uncontrolled administration has been associated with catastrophic side effects, which compromised its clinical use. To overcome these limitations, we aimed at developing a safer controlled and sustained release of BMP-2, utilizing poly(lactic-co-glycolic acid)-multistage vector composite microspheres (PLGA-MSV). The loading and release of BMP-2 from PLGA-MSV and its osteogenic potential in vitro and in vivo was evaluated. BMP-2 in vitro release kinetics was assessed by ELISA assay. It was found that PLGA-MSV achieved a longer and sustained release of BMP-2. Cell cytotoxicity and differentiation were evaluated in vitro by MTT and alkaline phosphatase (ALP) activity assays, respectively, with rat mesenchymal stem cells. The MTT results confirmed that PLGA-MSVs were not toxic to cells. ALP test demonstrated that the bioactivity of BMP-2 released from the PLGA-MSV was preserved, as it allowed for the osteogenic differentiation of rat mesenchymal stem cells, in vitro. The biocompatible, biodegradable, and osteogenic PLGA-MSVs system could be an ideal candidate for the safe use of BMP-2 in orthopedic tissue engineering applications.",
keywords = "BMP-2, Bone regeneration, Controlled release, Microsphere, PLGA, Silicon",
author = "Silvia Minardi and Fernandez-Moure, {Joseph S.} and Dongmei Fan and Murphy, {Matthew B.} and Yazdi, {Iman K.} and Xuewu Liu and Weiner, {Bradley K.} and Ennio Tasciotti",
year = "2020",
month = "2",
day = "1",
doi = "10.3390/pharmaceutics12020118",
language = "English (US)",
volume = "12",
journal = "Pharmaceutics",
issn = "1999-4923",
number = "2",

}

RIS

TY - JOUR

T1 - Biocompatible PLGA-mesoporous silicon microspheres for the controlled release of bmp-2 for bone augmentation

AU - Minardi, Silvia

AU - Fernandez-Moure, Joseph S.

AU - Fan, Dongmei

AU - Murphy, Matthew B.

AU - Yazdi, Iman K.

AU - Liu, Xuewu

AU - Weiner, Bradley K.

AU - Tasciotti, Ennio

PY - 2020/2/1

Y1 - 2020/2/1

N2 - Bone morphogenetic protein-2 (BMP-2) has been demonstrated to be one of the most vital osteogenic factors for bone augmentation. However, its uncontrolled administration has been associated with catastrophic side effects, which compromised its clinical use. To overcome these limitations, we aimed at developing a safer controlled and sustained release of BMP-2, utilizing poly(lactic-co-glycolic acid)-multistage vector composite microspheres (PLGA-MSV). The loading and release of BMP-2 from PLGA-MSV and its osteogenic potential in vitro and in vivo was evaluated. BMP-2 in vitro release kinetics was assessed by ELISA assay. It was found that PLGA-MSV achieved a longer and sustained release of BMP-2. Cell cytotoxicity and differentiation were evaluated in vitro by MTT and alkaline phosphatase (ALP) activity assays, respectively, with rat mesenchymal stem cells. The MTT results confirmed that PLGA-MSVs were not toxic to cells. ALP test demonstrated that the bioactivity of BMP-2 released from the PLGA-MSV was preserved, as it allowed for the osteogenic differentiation of rat mesenchymal stem cells, in vitro. The biocompatible, biodegradable, and osteogenic PLGA-MSVs system could be an ideal candidate for the safe use of BMP-2 in orthopedic tissue engineering applications.

AB - Bone morphogenetic protein-2 (BMP-2) has been demonstrated to be one of the most vital osteogenic factors for bone augmentation. However, its uncontrolled administration has been associated with catastrophic side effects, which compromised its clinical use. To overcome these limitations, we aimed at developing a safer controlled and sustained release of BMP-2, utilizing poly(lactic-co-glycolic acid)-multistage vector composite microspheres (PLGA-MSV). The loading and release of BMP-2 from PLGA-MSV and its osteogenic potential in vitro and in vivo was evaluated. BMP-2 in vitro release kinetics was assessed by ELISA assay. It was found that PLGA-MSV achieved a longer and sustained release of BMP-2. Cell cytotoxicity and differentiation were evaluated in vitro by MTT and alkaline phosphatase (ALP) activity assays, respectively, with rat mesenchymal stem cells. The MTT results confirmed that PLGA-MSVs were not toxic to cells. ALP test demonstrated that the bioactivity of BMP-2 released from the PLGA-MSV was preserved, as it allowed for the osteogenic differentiation of rat mesenchymal stem cells, in vitro. The biocompatible, biodegradable, and osteogenic PLGA-MSVs system could be an ideal candidate for the safe use of BMP-2 in orthopedic tissue engineering applications.

KW - BMP-2

KW - Bone regeneration

KW - Controlled release

KW - Microsphere

KW - PLGA

KW - Silicon

UR - http://www.scopus.com/inward/record.url?scp=85079246891&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85079246891&partnerID=8YFLogxK

U2 - 10.3390/pharmaceutics12020118

DO - 10.3390/pharmaceutics12020118

M3 - Article

VL - 12

JO - Pharmaceutics

T2 - Pharmaceutics

JF - Pharmaceutics

SN - 1999-4923

IS - 2

M1 - 118

ER -

ID: 58824515